Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Seeking neuroprotection in multiple sclerosis: an ongoing challenge
Jack P. Antel, … , Timothy E. Kennedy, Tanja Kuhlmann
Jack P. Antel, … , Timothy E. Kennedy, Tanja Kuhlmann
Published April 3, 2023
Citation Information: J Clin Invest. 2023;133(7):e168595. https://doi.org/10.1172/JCI168595.
View: Text | PDF
Commentary

Seeking neuroprotection in multiple sclerosis: an ongoing challenge

  • Text
  • PDF
Abstract

Multiple sclerosis (MS) is an autoimmune disease of the CNS, featuring inflammation and demyelination with variable recovery. In this issue of the JCI, Kapell, Fazio, and authors address the potential for targeting neuron-oligodendrocyte potassium shuttling at the nodes of Ranvier as a neuroprotective strategy during inflammatory demyelination of the CNS in experimental MS. Their extensive and impressive study could serve as a template for defining the physiologic properties of a putative protective pathway. The authors examined MS features in existent disease models, investigated the impact of pharmacologic intervention, and evaluated its status in tissues from patients with MS. We await future studies that will tackle the challenge of translating these findings into a clinical therapy.

Authors

Jack P. Antel, Timothy E. Kennedy, Tanja Kuhlmann

×

Figure 1

The Kir4.1/Kv7 pathway has a protective role under neuroinflammatory conditions.

Options: View larger image (or click on image) Download as PowerPoint
The Kir4.1/Kv7 pathway has a protective role under neuroinflammatory con...
(A) Organization of the specialized axonal domains and oligodendroglial myelin wrapping that flanks the node of Ranvier, including the paranode, juxtaparanode, and internode. (B) Neuronal excitability is regulated by outward-rectifying axonal Kv7 potassium channels at the nodes of Ranvier. Inward-rectifying Kir4.1 potassium channels expressed by OLs are localized to the inner tongue, outer tongue, and paranodal loops. Healthy OLs in normal conditions vacuum up the increased extracellular potassium that is released by neuronal activity. Kapell, Fazio, and colleagues report that inflammatory demyelinating conditions result in dysfunction of this neuroglial potassium shuttling mechanism, with downregulation of neuronal Kv7 channels and oligodendroglial Kir4.1 channels. The authors’ findings suggest that targeting potassium channel function to normalize neuronal excitability may prevent neurodegeneration and promote the recovery of function.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts